CompletedPhase 4

Effect of Recombinant Human Interferon α-2b Spray on Herpangina

China668 participantsStarted 2016-06-01

Plain-language summary

This is a multicenter, open，randomized controlled trial aiming to evaluate the effectiveness of recombinant human interferon α-2b spray compared with ribavirin treatment on pediatric patients with herpangina.

Who can participate

Age range1 Year – 7 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. meet the diagnostic criteria for pediatric herpangina;
✓. ages 1-7 years, no limitation for gender;
✓. within 72 hours of onset;
✓. the main organs (heart, liver, kidney and lung) function normally;
✓. follow up according to requirements and be hospitalized for observation;
✓. the guardian is fully informed and signed informed consent.

Exclusion criteria

✕. have allergy history of interferon;
✕. heart failure, respiratory insufficiency,liver and kidney dysfunction or severe malnutrition and other serious disease, or immunodeficient;
✕. children with epilepsy or other neurological disorders;
✕. other pathogens exist at the same time;
✕. the researchers believe that it is not appropriate to participate in this study.

What they're measuring

The defervesce rate during treatment by 72 hours

Timeframe: Measure the body temperature every 4 hours from starting of treatment to the 96th hour.

Trial details

NCT IDNCT03266601

SponsorChildren's Hospital of Fudan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-11-30

View on ClinicalTrials.gov More Herpangina trials